SCOTUS leans towards Sanofi-Regeneron in Amgen patent dispute.

The Supreme Court heard arguments in a patent dispute between Sanofi-Regeneron and Amgen over their competing PCSK9 inhibitors. Justices' questions hinted at a decision that will likely be a win for Sanofi and Regeneron. The case centers around Amgen's "genus" patent, which ostensibly covers 26 amino acid sequences related to antibodies targeting PCSK9. Sanofi-Regeneron argued that Amgen's patent is "over-claimed" and "under-enabled," while Amgen argued that its roadmap in the patent allows for such work to be done without undue experimentation. The Supreme Court's decision may provide an opportunity for good lawyers to have another issue to dispute in court.